Brought to you by 
Cyclacel and Xcyte in reverse merger
05 Jan 2006
Executive Summary
Cancer company Cyclacel will reverse merge with immune system therapeutics firm Xcyte to form Cyclacel Pharmaceuticals Inc., a public company that will have clinical- and preclinical-stage cancer candidates.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Stock
- Reverse Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cyclacel and Xcyte in reverse merger
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice